Impact of Fremanezumab on Headache-related Disability in Patients With Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medication Classes in the Open–label Extension of the Phase 3b FOCUS Study (4416)
Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available